Tralesinidase alfa clinical trials
Also written AX 250.
How each study uses tralesinidase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tralesinidase alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AX 250
- 3
Studies by the year they started
4 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tralesinidase alfa.
- Oct 2027Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLEPhase 4 · Allievex Corporation
Studies
Open first, then newest update. How each study uses tralesinidase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)Not yet recruitingPhase 3Spruce BiosciencesNCT07579910Written as Tralesinidase alfa (TA)
- Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLEEnrolling by invitationPhase 4Allievex CorporationNCT05492799Written as AX 250
- A Treatment Extension Study of Mucopolysaccharidosis Type IIIBStatus unknownPhase 2Allievex CorporationNCT03784287Written as AX 250
- A Treatment Study of Mucopolysaccharidosis Type IIIBCompletedPhase 1/2Allievex CorporationNCT02754076Written as AX 250
Codes
What other systems call tralesinidase alfa · ClinicalTrials.gg INT015988
- UNII (FDA) AA60A4ST8XTRALESINIDASE ALFAOne source FDA
- NCI Thesaurus C152709Tralesinidase AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AA60A4ST8X | TRALESINIDASE ALFA | One source FDA |
| NCI Thesaurus | C152709 | Tralesinidase Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.